

# Press Release

OCTOBER 2013

*Extending the Activity  
of Biologics Beyond  
Protein Engineering*



## Patent is Issued for i-novion's Platform Technology

**Randolph, New Jersey** — October 8, 2013 — I-novion, Inc. announced today that the United States Patent and Trademark Office has issued a new patent covering the Company's platform technology. US Patent number 8,551,531 relates to i-novion's library of pentablock copolymer (PBC) compositions for extended release drug delivery.

"This patent covers ground-breaking technology discovered and developed by Professor Ashim K. Mitra and his team at the University of Missouri – Kansas City (UMKC) that serves as a foundation for i-novion's extended release product development activities," said Dr. Ulrich M. Grau, Chairman of i-novion's Board of Directors. I-novion holds an exclusive world-wide license to PBC technology from the University of Missouri – Kansas City for use in all fields of application.

I-novion's PBCs are highly versatile, allowing the design of compositions that encapsulate small molecules and biologics in nanoparticles for sustained release. PBCs can also be designed to form thermosensitive polymers that when dissolved in aqueous medium are free-flowing at room temperature and become gel at body temperature. Drug-loaded nanoparticles can be suspended in gelling polymer for delivery through a syringe. For instance, such formulations may be injected and deliver antibody fragments for 6 months or more.

### **About i-novion, Inc.**

I-novion is a private company owned by its founders. Located in New Jersey, i-novion collaborates with pharmaceutical and biotechnology companies for the application of its technology in the development of novel proprietary therapeutic products. I-novion is also developing its internal pipeline of products.

#### CONTACT

*For inquiries about technology  
partnerships please contact:*

**Ulrich M. Grau, Ph.D.**  
uli.grau@i-novion.com

**[www.i-novion.com](http://www.i-novion.com)**